Home » Topics » BioWorld Science

BioWorld Science
RSS

Sunrise Technologies will expand phase II LTK trials

April 26, 1996

VIMRx acquires rights to compounds based on RILON technology

April 26, 1996

SKB receives rights to OraSolve dosage technology from CIMA

April 26, 1996

Oxford Molecular, Yamanouchi to codevelop ion channel modulators

April 26, 1996

RMP-7 advances to phase I/II in Europe

April 26, 1996

SIBIA, Ciba-Geigy extend drug discovery agreement

April 26, 1996

Roche licenses access to LIFESEQ database

April 26, 1996

SIBIA, Salk Institute expand agreement for NAChRs

April 26, 1996

New antidepressants disclosed by Yamanouchi

April 26, 1996

Mitsui Seiyaku describes sigma-opioid antagonist

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...